ZYDUS LIFESCIENCES
GenericsZYDUS LIFESCIENCES is a generic drug manufacturer focused on Cardiovascular, Dermatology, Metabolic. Key products include ZITUVIO.
ZYDUS LIFESCIENCES at a Glance
- Strong track record with 84% execution quality across 20 trials
- Fast trial execution (10 months median completion)
ZYDUS LIFESCIENCES's Key Drugs
ZYDUS LIFESCIENCES's core commercial portfolio centers on DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, ZITUVIO, spanning Cardiovascular and Dermatology — its most strategically important drugs approved in the last 15 years.
Breast Cancer
Hypertension
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes
ZYDUS LIFESCIENCES's Recent FDA Approvals
ZYDUS LIFESCIENCES secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
ZYDUS LIFESCIENCES's Therapeutic Areas
ZYDUS LIFESCIENCES's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Dermatology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ZYDUS LIFESCIENCES's Top Competitors
ZYDUS LIFESCIENCES's closest competitors by therapeutic-area and drug-target overlap include AstraZeneca, Novartis, and Boehringer Ingelheim. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ZYDUS LIFESCIENCES Pipeline Snapshot
ZYDUS LIFESCIENCES has 6 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 1 Phase 2 and 4 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/4 completed
- • Speed: 10 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (7)
Discontinued (2)
Company Info
- First Approval
- 2005-04-20
- Latest
- 2026-06-01
- Applications
- 108
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges